Clinical Trial Update: Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics [Phase 4]

View source ↗

Summary

This clinical trial registry entry outlines a Phase 4 study investigating mechanisms of resistance to lorlatinib induction therapy in resectable ALK-positive no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lorbrena (lorlatinib)

Snippet

Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: NSCLC | Phase 4 | Status: NOT_YET_RECRUITING